Cerebral Venous Thrombosis

Cerebral venous sinus thrombosis (CVST) is thrombosis of the dural venous sinuses and/or cortical cerebral veins, obstructing venous drainage of the brain. Unlike arterial stroke — which follows well-defined vascular territories — CVST produces venous hypertension, cytotoxic and vasogenic edema, and hemorrhagic venous infarction in a distribution that does not respect arterial boundaries. It disproportionately affects young adults and women of childbearing age; oral contraceptive use is the single most common identifiable risk factor in developed countries. Because headache is the predominant and often isolated presenting symptom and brain computed tomography (CT) is frequently normal, CVST is among the most commonly missed neurological diagnoses. Prompt recognition and anticoagulation are critical — most patients recover fully with treatment, but delayed diagnosis leads to irreversible brain injury and death.

Cerebral Venous Thrombosis — scientific infographic poster

Table of Contents

  1. Overview
  2. Epidemiology
  3. Venous Anatomy and Affected Sinuses
  4. Pathophysiology
  5. Etiology and Risk Factors
  6. Clinical Presentation
  7. Diagnosis
  8. Treatment
  9. Prognosis and Outcomes
  10. Special Populations
  11. Key Research and Recent Advances
  12. Key Research Papers
  13. Featured Videos

1. Overview

CVST encompasses thrombosis affecting the large dural venous sinuses (superior sagittal sinus, lateral/transverse sinuses, straight sinus, cavernous sinus) as well as the smaller cortical veins draining into them. The superior sagittal sinus is involved in more than 50% of cases, followed by the lateral sinuses (44%), straight sinus (18%), and cortical veins (17%); multiple sinus involvement occurs in approximately 30% of cases. The condition is distinguished from idiopathic intracranial hypertension (IIH/pseudotumor cerebri), arterial stroke, encephalitis, and brain tumor — all of which can present with headache, papilledema, or focal deficits.

A landmark shift in CVST understanding occurred in 2021 with the recognition of vaccine-induced immune thrombocytopenia and thrombosis (VITT), a rare but severe CVST syndrome triggered by adenovirus-vector COVID-19 vaccines. VITT-associated CVST is characterized by antibodies against platelet factor 4 (anti-PF4). It clinically mimics heparin-induced thrombocytopenia (HIT type 2) and is treated differently — heparin is contraindicated, and intravenous immunoglobulin (IVIG) is first-line. This discovery has reinforced the importance of checking platelet count in every CVST patient before starting anticoagulation.

2. Epidemiology

The annual incidence of CVST is approximately 1.32–1.57 cases per 100,000 population, making it far less common than arterial stroke but with similar or greater diagnostic challenge due to variable presentation. Women are disproportionately affected, with a female-to-male ratio of approximately 3:1 overall, driven by oral contraceptive use and pregnancy/puerperium risk. The peak incidence is in young adults aged 20–35 years, though CVST occurs at all ages including neonates and children (where infection and dehydration are the leading causes) and the elderly (where malignancy and hyperviscosity predominate).

The American Heart Association's 2024 statement says CVST accounts for 0.5% to 3% of all strokes. Its share among strokes in women under 45 years of age is sometimes given as up to 15%; no source for that figure was found. Despite its rarity, CVST is important because it disproportionately affects young productive adults and, with prompt treatment, carries substantially better outcomes than arterial stroke (case fatality 8–10% in modern series, compared to 25–30% for large-vessel arterial stroke). In-hospital mortality in contemporary cohorts is 3–4% with appropriate anticoagulation.

3. Venous Anatomy and Affected Sinuses

The dural venous sinuses are endothelium-lined venous channels within the dura mater, lacking valves (allowing bidirectional flow) and receiving drainage from cortical veins, diploic veins (skull), and emissary veins (scalp). Key sinuses and their clinical correlates:

4. Pathophysiology

CVST causes brain injury through two simultaneous mechanisms that often coexist in the same patient, accounting for the heterogeneous magnetic resonance imaging (MRI) appearance:

Venous Hypertension and Edema

Thrombotic obstruction of a venous sinus raises venous pressure in draining cortical veins. When venous pressure exceeds capillary perfusion pressure, cerebral blood flow in the drained territory falls — a mechanism fundamentally different from arterial occlusion. The resulting edema is initially vasogenic (blood-brain barrier disruption from venous hypertension) and, as ischemia deepens, becomes cytotoxic. Critically, venous collateral drainage (leptomeningeal veins, diploic channels) often develops rapidly, limiting infarction — this explains why large superior sagittal sinus thromboses can present with only headache and papilledema with no parenchymal injury, while smaller thrombi in poor-collateral territories cause massive hemorrhagic infarction.

Hemorrhagic Venous Infarction

When venous hypertension exceeds the capacity of collateral drainage, venules rupture into the parenchyma, producing hemorrhagic venous infarction. These lesions do not follow arterial territories, are often bilateral and parasagittal (for superior sagittal sinus thrombosis), and typically show surrounding edema exceeding the hemorrhage volume. The hemorrhagic nature of CVST lesions historically led to withholding of anticoagulation — a practice later studies did not support: the heparin trials reported no new symptomatic brain hemorrhages with anticoagulation, even in patients who already had a hemorrhage, and fewer deaths and less dependency that did not reach statistical significance when pooled.

Raised Intracranial Pressure

Impaired cerebrospinal fluid (CSF) absorption at arachnoid granulations (which drain into the superior sagittal sinus) — combined with reduced venous capacitance — raises intracranial pressure (ICP). This mechanism is responsible for the IIH-like syndrome of isolated intracranial hypertension seen in lateral sinus thrombosis, with headache and papilledema but no focal deficits or parenchymal injury.

5. Etiology and Risk Factors

Hormonal and Pregnancy-Related (Young Women)

Thrombophilia

Infection

Malignancy and Hematological Disorders

Other Causes

6. Clinical Presentation

Headache — The Cardinal Symptom

Headache is the presenting symptom in approximately 90% of CVST patients and is the sole symptom in 25% of isolated intracranial hypertension presentations. Unlike the thunderclap headache of subarachnoid hemorrhage, CVST headache typically has a subacute onset over days to weeks, is diffuse, progressive, and worsening — often positional (worse lying flat due to elevated ICP) or worsening with Valsalva. However, thunderclap CVST onset does occur (15% of cases) and is part of the differential diagnosis of sudden severe headache alongside subarachnoid hemorrhage. The headache may be accompanied by nausea, vomiting, and photophobia, mimicking migraine or tension headache — leading to delayed diagnosis of 1–4 weeks on average.

Focal Neurological Deficits

Seizures

Seizures occur in approximately 40% of CVST patients — a substantially higher rate than arterial stroke (8–10%), reflecting cortical irritation from hemorrhagic venous infarction and perilesional edema. Focal-onset seizures with secondary generalization are most common; status epilepticus occurs in 5–10% and carries significantly worse prognosis. Early seizures (within 2 weeks) predict higher risk of further seizures but do not independently worsen long-term outcome when controlled. The 2017 European Stroke Organization guideline suggests antiepileptic drugs in people who have had an early seizure and have lesions in the upper part of the brain (supratentorial lesions), to prevent further early seizures. It could make no recommendation on preventing later seizures, and it gives no length of treatment.

Isolated Intracranial Hypertension Syndrome

Approximately 20–40% of CVST — predominantly lateral sinus thrombosis — presents as isolated intracranial hypertension without focal deficits or parenchymal injury, clinically indistinguishable from idiopathic intracranial hypertension (IIH/pseudotumor cerebri). These patients have headache, papilledema, and visual obscurations; cerebrospinal fluid opening pressure is elevated; brain magnetic resonance imaging parenchyma is normal. The 2018 UK consensus guidelines on idiopathic intracranial hypertension call CT or MR venography mandatory to exclude cerebral sinus thrombosis, and call for more in-depth investigation in patients who are not female, not of childbearing age, or have a body mass index below 30.

Cavernous Sinus Thrombosis

Septic cavernous sinus thrombosis presents with periorbital edema, proptosis, chemosis, ophthalmoplegia (cranial nerves III, IV and VI), and retinal venous congestion, often progressing from unilateral to bilateral within 24–48 hours via the intercavernous sinus. Fever, leukocytosis, and identifiable primary infection source (facial cellulitis, sinusitis, dental abscess) differentiate septic CST from aseptic orbital apex syndrome. Urgent antibiotics (with antifungal cover if mucormycosis is suspected in immunocompromised or diabetic patients) are primary therapy.

Encephalopathy and Coma

Progressive encephalopathy, bilateral thalamic dysfunction, coma, or decerebrate posturing indicate deep venous involvement (straight sinus ± Galen vein thrombosis) — the most severe presentation with the worst prognosis. Bilateral thalamic hyperintensity on magnetic resonance imaging in a young patient without arterial risk factors is a recognized pointer to deep CVST.

7. Diagnosis

Brain Computed Tomography — Initial Emergency Scan

Non-contrast computed tomography is typically the first imaging obtained. It may show:

Magnetic Resonance Imaging Brain + magnetic resonance venography — Gold Standard

Magnetic resonance imaging with magnetic resonance venography is the gold standard investigation, with sensitivity approaching 90–95% for CVST when T1, T2, fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and time-of-flight (TOF) magnetic resonance venography sequences are combined:

Laboratory Investigations

Lumbar Puncture

Lumbar puncture can be performed safely after imaging confirms no mass lesion or significant midline shift. Cerebrospinal fluid findings in CVST: elevated opening pressure (often >25 cmH2O), mildly elevated protein (50–100 mg/dL), mild pleocytosis (<50 cells/mm³), or xanthochromia (if subarachnoid blood). Lumbar puncture is also therapeutic for severe papilledema with visual deterioration (reduces ICP acutely). Cerebrospinal fluid analysis also helps exclude meningitis/encephalitis, which may coexist with or mimic CVST.

8. Treatment

Anticoagulation — First-Line Therapy

Anticoagulation is the cornerstone of CVST treatment, despite the frequent presence of hemorrhagic venous infarction. It rests on two small but influential randomized controlled trials (Einhäupl 1991; de Bruijn 1999). A 2011 Cochrane review pooled them (79 patients): the relative risk of death was 0.33 (95% confidence interval 0.08 to 1.21) and of death or dependency 0.46 (0.16 to 1.31), a potentially important reduction that did not reach statistical significance. No new symptomatic brain hemorrhages were seen, and one major gastrointestinal hemorrhage occurred after anticoagulant treatment. The pathophysiological rationale is compelling: anticoagulation arrests thrombosis propagation and allows natural thrombolysis to restore venous drainage, reducing venous hypertension and preventing further infarction. The hemorrhagic component of venous infarction does not worsen significantly with anticoagulation — it is a consequence of venous hypertension, not the anticoagulant.

Endovascular Thrombectomy and Local Thrombolysis

Endovascular treatment — mechanical thrombectomy (aspiration, stent-retriever) ± local catheter-directed thrombolysis (urokinase, tissue plasminogen activator) via the venous sinuses — is reserved for patients with severe CVST deteriorating despite therapeutic anticoagulation. The ISCVT registry identifies factors predicting poor outcome with anticoagulation alone: coma (Glasgow Coma Scale below 9), deep venous thrombosis, intracranial hemorrhage at presentation, and bilateral motor deficits. Uncontrolled case series report recanalization in 70–80% of treated patients. The one randomized trial, TO-ACT (67 patients with severe disease, published 2020), was halted early for futility: a good outcome at 12 months was seen in 67% with endovascular treatment and 68% with standard care (relative risk 0.99), and deaths were 12% against 3%, a difference that was not statistically significant (P = .20). Its authors say the treatment did not appear to improve outcome, and that the small size leaves open the possibility that future studies show better recovery. The 2017 European Stroke Organization guideline could make no recommendation on thrombolysis or thrombectomy. Endovascular treatment is reserved for ≤10% of CVST cases.

Antiepileptic Drugs (AEDs)

The 2017 European Stroke Organization guideline suggests antiepileptics in patients with an early seizure and supratentorial lesions, to prevent further early seizures. It does not extend this to people who have had no seizure, although seizures are common in this disease (about 40%). Levetiracetam is often chosen (minimal drug interactions, no hepatic induction). Valproate and phenytoin are alternatives. Duration: the guideline made no recommendation on later seizures or on a length of treatment; in practice some patients with cortical lesions continue for 1 year, with earlier stopping described in those without seizures and with lesion resolution. Routine prophylaxis in patients without cortical lesions is not strongly supported by evidence.

Intracranial Pressure Management

Infection Treatment (Septic CVST)

Intravenous antibiotics covering the causative pathogen are the core of treatment and are started immediately upon suspicion of septic CVST, before culture results return. Empiric coverage: vancomycin + ceftriaxone ± metronidazole (for anaerobes from dental/sinus source). Duration typically 4–6 weeks intravenous (IV) followed by oral completion. Surgical source control (mastoidectomy, sinus drainage, dental extraction) is required for ongoing infectious foci — failure to control the source leads to refractory septic thrombosis. Anticoagulation in septic CVST remains controversial but is used at most centers for deteriorating patients without contraindication.

9. Prognosis and Outcomes

Modern CVST prognosis is substantially better than historical series, reflecting improved recognition and universal anticoagulation. The International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT, n=624) established the best available natural history data:

Recovery can leave problems these numbers do not show. In the SECRET trial, people on average reported reduced quality of life, low mood, fatigue and headache, with impaired thinking on testing, at enrollment; all of these improved markedly by day 180.

The American Heart Association's 2024 statement says death or dependence occurs in 10% to 15% of patients despite intensive medical treatment.

Predictors of Poor Outcome (ISCVT Data)

VITT-Associated CVST (Separate UK Studies)

Recanalization

Partial or complete sinus recanalization is commonly given as approximately 80% of patients with anticoagulation, most within 3–6 months of treatment. The RE-SPECT CVT trial measured 60.0% on dabigatran and 67.3% on warfarin at 25 weeks, and in the SECRET trial every participant had at least partial reopening by day 180, so the number depends on how partial reopening is counted. Recanalization correlates with better functional outcomes but is not universal; partial or absent recanalization does not preclude good functional recovery if collateral drainage is adequate. Magnetic resonance venography at 3–6 months after treatment is used to assess recanalization and guide anticoagulation duration decisions.

10. Special Populations

Pregnancy and Puerperium

LMWH is safe in pregnancy (does not cross the placenta) and is the anticoagulant of choice throughout pregnancy. In customary practice, UFH replaces it at 36 weeks to allow neuraxial anesthesia planning. Post-partum: LMWH restarts within 12–24 hours of delivery, with transition to warfarin after 6–12 weeks. The DOAC-CVT study treated pregnancy and lactation as an absolute contraindication to direct oral anticoagulants as a class, not to dabigatran alone. The 2017 European Stroke Organization guideline suggests that subsequent pregnancies are safe and that prophylactic LMWH be considered throughout pregnancy and the puerperium. It also suggests that women who have had this clot avoid contraceptives containing estrogen; its wording covers estrogen-containing products, not all contraception.

Pediatric CVST

Neonatal CVST: most commonly presents with seizures in the first week of life; superior sagittal sinus and straight sinus predominantly affected; dehydration, perinatal asphyxia, infection are common causes; treatment with LMWH is reasonable but evidence base is weaker than adults; outcome generally good with appropriate treatment. Childhood/adolescent CVST: head/neck infection (otitis media, mastoiditis), leukemia, L-asparaginase chemotherapy, and iron-deficiency anemia are important causes not seen in adults.

Elderly CVST

Malignancy, myeloproliferative neoplasms, dehydration from intercurrent illness, and direct oral anticoagulant interruption or under-dosing are the primary etiologies. Presentation may be atypical (encephalopathy, confusion) without prominent headache. Higher hemorrhagic risk with anticoagulation in elderly; balance individualized.

11. Key Research and Recent Advances

The RE-SPECT CVT trial (2019, n=120) was an exploratory randomized trial of dabigatran (150 mg twice daily) against warfarin after CVST. No repeat clots occurred in either group, major bleeding was 1.7% against 3.3%, and recanalization was 60.0% against 67.3%; its authors concluded both drugs may be safe and effective. It was the first randomized trial of a direct oral anticoagulant in CVST. Rivaroxaban has since been tested in the small SECRET feasibility trial (2023), and the DOAC-CVT cohort (2025) found no difference in clots or major bleeding against warfarin-type drugs.

The identification of VITT as a CVST-specific syndrome in 2021 (Greinacher et al., NEJM; Schultz et al., NEJM) transformed understanding of immune-mediated thrombosis. VITT mimics HIT type 2 mechanistically (anti-PF4 immunoglobulin G antibodies triggering FcγRIIA-mediated platelet activation) but without prior heparin exposure. The clinical lesson drawn from this work is that a platelet count in every CVST patient, and anti-PF4 antibody testing after a recent adenovirus-vector vaccine, can identify this syndrome, in which heparin is contraindicated and immunoglobulin was linked to better outcomes (see Prognosis).

The TO-ACT randomized trial (2020, 67 patients) found no apparent improvement from endovascular treatment in severe CVST (see Treatment). The American Heart Association updated its scientific statement in 2024, replacing its 2011 statement: this clot causes 0.5% to 3% of strokes, and death or dependence occurs in 10% to 15% of patients despite intensive medical treatment.

Emerging biomarker research focuses on serum glial fibrillary acidic protein (astrocyte injury), neurofilament light chain (axonal injury), and D-dimer trajectory as predictors of CVST severity and recanalization. Artificial intelligence analysis of MRI-magnetic resonance venography for automated sinus signal abnormality detection is under active development to reduce diagnostic delay.

Key Research Papers

  1. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664–670. — PubMed PMID: 14976332
  2. Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40(7):2356–2361. — PubMed PMID: 19478226
  3. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338(8767):597–600. — PubMed PMID: 1679154
  4. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30(3):484–488. — PubMed PMID: 10066840
  5. Ferro JM, Coutinho JM, Dentali F, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76(12):1457–1465. — PubMed PMID: 31479105
  6. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. — PubMed PMID: 33835769
  7. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791–1798. — PubMed PMID: 15858188
  8. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis. Stroke. 2011;42(4):1158–1192. — PubMed PMID: 21293023
  9. Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nat Rev Neurol. 2017;13(9):555–565. — PubMed PMID: 28820187
  10. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108(4):1129–1134. — PubMed PMID: 16609071
  11. Ferro JM, Bousser MG, Canhão P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203–1213. — PubMed PMID: 28833980
  12. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016;47(9):2180–2182. — PubMed PMID: 27435401
  13. Coutinho JM, Zuurbier SM, Bousser MG, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol. 2020;77(8):966–973. — PubMed PMID: 32421159
  14. Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev. 2011;2011(8):CD002005. — PubMed PMID: 21833941
  15. Saposnik G, Bushnell C, Coutinho JM, et al. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke. 2024;55(3):e77–e90. — PubMed PMID: 38284265
  16. van de Munckhof A, van Kammen MS, Tatlisumak T, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24(3):199–207. — PubMed PMID: 39986309
  17. Field TS, Dizonno V, Almekhlafi MA, et al. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis. Stroke. 2023;54(11):2724–2736. — PubMed PMID: 37675613
  18. Perry RJ, Tamborska A, Singh B, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398(10306):1147–1156. — PubMed PMID: 34370972
  19. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680–1689. — PubMed PMID: 34379914
  20. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–1100. — PubMed PMID: 29903905

PubMed Topic Searches

  1. PubMed: Cerebral venous sinus thrombosis anticoagulation treatment
  2. PubMed: CVST diagnosis MRI MRV
  3. PubMed: Cerebral venous thrombosis oral contraceptives thrombophilia
  4. PubMed: VITT vaccine-induced immune thrombocytopenia and thrombosis CVST
  5. PubMed: Cerebral venous thrombosis prognosis recanalization

Back to Table of Contents

Connections